524 related articles for article (PubMed ID: 23396211)
1. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Reilly SM; Chiang SH; Decker SJ; Chang L; Uhm M; Larsen MJ; Rubin JR; Mowers J; White NM; Hochberg I; Downes M; Yu RT; Liddle C; Evans RM; Oh D; Li P; Olefsky JM; Saltiel AR
Nat Med; 2013 Mar; 19(3):313-21. PubMed ID: 23396211
[TBL] [Abstract][Full Text] [Related]
2. Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Cruz VH; Arner EN; Wynne KW; Scherer PE; Brekken RA
Mol Metab; 2018 Oct; 16():139-149. PubMed ID: 29935921
[TBL] [Abstract][Full Text] [Related]
3. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKε for the treatment of obesity.
Beyett TS; Gan X; Reilly SM; Gomez AV; Chang L; Tesmer JJG; Saltiel AR; Showalter HD
Bioorg Med Chem; 2018 Nov; 26(20):5443-5461. PubMed ID: 30270002
[TBL] [Abstract][Full Text] [Related]
5. Turning off the inflammatory, but not the metabolic, flames.
Calay ES; Hotamisligil GS
Nat Med; 2013 Mar; 19(3):265-7. PubMed ID: 23467233
[No Abstract] [Full Text] [Related]
6. Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.
Oral EA; Reilly SM; Gomez AV; Meral R; Butz L; Ajluni N; Chenevert TL; Korytnaya E; Neidert AH; Hench R; Rus D; Horowitz JF; Poirier B; Zhao P; Lehmann K; Jain M; Yu R; Liddle C; Ahmadian M; Downes M; Evans RM; Saltiel AR
Cell Metab; 2017 Jul; 26(1):157-170.e7. PubMed ID: 28683283
[TBL] [Abstract][Full Text] [Related]
7. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
[TBL] [Abstract][Full Text] [Related]
8. Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Zhou Z; Qi J; Zhao J; Lim CW; Kim JW; Kim B
J Cell Mol Med; 2020 Jan; 24(2):1383-1398. PubMed ID: 31821710
[TBL] [Abstract][Full Text] [Related]
9. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.
Mowers J; Uhm M; Reilly SM; Simon J; Leto D; Chiang SH; Chang L; Saltiel AR
Elife; 2013 Dec; 2():e01119. PubMed ID: 24368730
[TBL] [Abstract][Full Text] [Related]
10. FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition.
Reilly SM; Abu-Odeh M; Ameka M; DeLuca JH; Naber MC; Dadpey B; Ebadat N; Gomez AV; Peng X; Poirier B; Walk E; Potthoff MJ; Saltiel AR
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822771
[TBL] [Abstract][Full Text] [Related]
11. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
Möller M; Wasel J; Schmetzer J; Weiß U; Meissner M; Schiffmann S; Weigert A; Möser CV; Niederberger E
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630674
[TBL] [Abstract][Full Text] [Related]
12. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Qi J; Zhou Z; Lim CW; Kim JW; Kim B
Toxicol Appl Pharmacol; 2019 Dec; 385():114767. PubMed ID: 31697998
[TBL] [Abstract][Full Text] [Related]
13. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
14. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Beyett TS; Gan X; Reilly SM; Chang L; Gomez AV; Saltiel AR; Showalter HD; Tesmer JJG
Mol Pharmacol; 2018 Oct; 94(4):1210-1219. PubMed ID: 30082428
[TBL] [Abstract][Full Text] [Related]
15. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
16. Chrysin modulates protein kinase IKKε/TBK1, insulin sensitivity and hepatic fatty infiltration in diet-induced obese mice.
Amir Siddiqui M; Badruddeen ; Akhtar J; Uddin S; Chandrashekharan SM; Ahmad M; Khan MI; Khalid M
Drug Dev Res; 2022 Feb; 83(1):194-207. PubMed ID: 34350600
[TBL] [Abstract][Full Text] [Related]
17. The protein kinase IKKepsilon regulates energy balance in obese mice.
Chiang SH; Bazuine M; Lumeng CN; Geletka LM; Mowers J; White NM; Ma JT; Zhou J; Qi N; Westcott D; Delproposto JB; Blackwell TS; Yull FE; Saltiel AR
Cell; 2009 Sep; 138(5):961-75. PubMed ID: 19737522
[TBL] [Abstract][Full Text] [Related]
18. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
[TBL] [Abstract][Full Text] [Related]
20. TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue.
Zhao P; Wong KI; Sun X; Reilly SM; Uhm M; Liao Z; Skorobogatko Y; Saltiel AR
Cell; 2018 Feb; 172(4):731-743.e12. PubMed ID: 29425491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
